Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02935517 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)
A Phase 1 study of Achromatopsia, sponsored by Beacon Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 6
- Study locations
NCT02935517: Active Phase 1 study of Achromatopsia, sponsored by Beacon Therapeutics.
NCT02935517 is a Phase 1 study of Achromatopsia that is active but no longer recruiting, run by Beacon Therapeutics. The registered enrollment target is 24 participants, below the 6,696-participant average among 3 other Achromatopsia trials with a reported enrollment target (100% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02935517, a Phase 1 study of Achromatopsia, is active but no longer recruiting, sponsored by Beacon Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 6
- Study locations
Study Summary
This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of AGTC-402, administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGA3 gene. The primary study endpoint will be safety and the secondary study endpoint will be efficacy.
Conditions Studied
Interventions
- BIOLOGICAL AGTC-402
Study Locations (6)
Florida
- VitreoRetinal Associates - Gainesville
- Bascom Palmer Eye Institute - Miami
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
Ohio
- Cincinnati Eye Institute - Cincinnati
Oregon
- Casey Eye Institute, Oregon Health and Sciences University - Portland
Other
- Hadassah-Hebrew University Medical Center - Jerusalem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-08-03 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
What the registry record for NCT02935517 still lists
NCT02935517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 6,696-participant average among 3 other Achromatopsia trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Achromatopsia appearing as the primary indexed condition, and to 1 intervention - of which AGTC-402 is the first listed.
NCT02935517 lists 6 locations in 5 states (Florida, Massachusetts, Ohio).
Frequently Asked Questions
What is clinical trial NCT02935517 about?
NCT02935517 is a clinical study titled "Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)". This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of AGTC-402, administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGA3 gene. The primary study endpoint will be safety and the secondary study endpoint will ...
What is the current status of trial NCT02935517?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-08-03. Estimated completion is 2026-08.
What conditions does trial NCT02935517 study?
This clinical trial studies the following conditions: Achromatopsia.
What interventions are being tested in trial NCT02935517?
The interventions under investigation include: AGTC-402 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02935517?
This trial is sponsored by Beacon Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02935517 being conducted?
This trial has 6 study locations across Florida, Massachusetts, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Achromatopsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI